Login to Your Account

Clinic Roundup

Wednesday, February 29, 2012

• AVI BioPharma Inc., of Bothell, Wash., said it received approval from the FDA to proceed with a single oligomer, AVI-7288, in studies in both humans and nonhuman primates to support the safety and efficacy of post-exposure prophylaxis against Marburg virus infection. AVI-7288 is one of the two components that make up AVI-6003. AVI is conducting the work under a Department of Defense contract.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription